A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Focal Segmental Glomerulosclerosis (FSGS)
Latest Information Update: 18 Mar 2025
At a glance
- Drugs Ilacirnon (Primary)
- Indications Focal segmental glomerulosclerosis
- Focus Therapeutic Use
- Acronyms LUMINA1
- Sponsors Amgen; ChemoCentryx
Most Recent Events
- 02 Apr 2021 Status changed from active, no longer recruiting to completed.
- 15 Jul 2020 This trial has been completed in United Kingdom according to European Clinical Trials Database record.
- 08 Jul 2020 This trial has been completed in Poland according to European Clinical Trials Database record.